EZH2 inhibition was demonstrated to restore the cytotoxic response of CD8 T cells in patients with systemic lupus erythematosus (SLE), inhibiting the incidence of infection and thus reducing death resulting from infection22. The gene discussed is CD8A; the disease is systemic lupus erythematosus.